TDMS Study 05037-04 Pathology Tables
NTP Experiment-Test: 05037-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PENTACHLOROANISOLE Date: 06/23/97
Route: GAVAGE Time: 12:31:18
Facility: Southern Research Institute
Chemical CAS #: 1825-21-4
Lock Date: None
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include 001 VEHICLE CONTROL
Include 004 VEHICLE CONTROL
Include 007 40 MG/KG
Include 010 40 MG/KG
Include 013 20 MG/KG
Include 016 20 MG/KG
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05037-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PENTACHLOROANISOLE Date: 06/23/97
Route: GAVAGE Time: 12:31:18
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 20 MG/KG 40 MG/KG
CONTROL
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50
Early Deaths
Moribund Sacrifice 17 18 29
Natural Death 8 6 5
Accidently Killed 1
Dosing Accident 1
Survivors
Terminal Sacrifice 24 25 16
Animals Examined Microscopically 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Cecum (43) (21) (49)
Intestine Small, Duodenum (48) (21) (49)
Polyp Adenomatous 1 (2%)
Intestine Small, Jejunum (48) (23) (49)
Adenocarcinoma 1 (2%)
Sarcoma 1 (2%)
Liver (50) (50) (50)
Hemangiosarcoma 1 (2%)
Hepatoblastoma 1 (2%)
Hepatocellular Carcinoma 4 (8%) 2 (4%) 2 (4%)
Hepatocellular Adenoma 8 (16%) 6 (12%) 10 (20%)
Hepatocellular Adenoma, Multiple 2 (4%) 2 (4%)
Hepatocholangiocarcinoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Sarcoma 1 (2%)
Mesentery (25) (18) (24)
Cholangiocarcinoma, Metastatic, Liver 1 (4%)
Fibrosarcoma 1 (4%)
Hemangiosarcoma 1 (4%) 2 (8%)
Sarcoma 1 (4%) 2 (11%)
Pancreas (50) (28) (50)
Cholangiocarcinoma, Metastatic, Liver 1 (2%)
Fibrosarcoma 1 (2%)
Sarcoma 1 (2%)
Salivary Glands (50) (25) (49)
Hemangiosarcoma 1 (2%)
Stomach, Forestomach (50) (45) (50)
Sarcoma 1 (2%)
Squamous Cell Papilloma 2 (4%)
Stomach, Glandular (50) (44) (50)
Carcinoid Tumor Malignant 1 (2%)
Page 2
NTP Experiment-Test: 05037-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PENTACHLOROANISOLE Date: 06/23/97
Route: GAVAGE Time: 12:31:18
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 20 MG/KG 40 MG/KG
CONTROL
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Tooth (1)
Sarcoma 1 (100%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (25) (50)
Cholangiocarcinoma, Metastatic, Liver 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (50) (50) (49)
Adrenal Gland, Medulla (50) (49) (48)
Pheochromocytoma Benign 1 (2%)
Islets, Pancreatic (50) (25) (50)
Pituitary Gland (47) (49) (50)
Pars Distalis, Adenoma 7 (15%) 5 (10%) 3 (6%)
Pars Intermedia, Adenoma 1 (2%)
Thyroid Gland (50) (50) (50)
Follicular Cell, Adenoma 1 (2%)
Follicular Cell, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (45) (36) (50)
Cystadenoma, Papillary 1 (2%) 2 (4%)
Hemangioma 1 (2%)
Luteoma 1 (3%)
Sarcoma 1 (3%)
Teratoma Malignant 1 (2%)
Teratoma NOS 1 (3%)
Uterus (46) (43) (50)
Adenoma 1 (2%)
Fibrous Histiocytoma Malignant 1 (2%)
Hemangioma 1 (2%)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Leiomyoma 1 (2%)
Leiomyosarcoma 1 (2%)
Sarcoma 2 (5%) 1 (2%)
Page 3
NTP Experiment-Test: 05037-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PENTACHLOROANISOLE Date: 06/23/97
Route: GAVAGE Time: 12:31:18
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 20 MG/KG 40 MG/KG
CONTROL
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - cont
Sarcoma Stromal 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (25) (50)
Hemangiosarcoma 2 (4%) 1 (2%)
Lymph Node (50) (50) (50)
Bronchial, Cholangiocarcinoma, Metastatic,
Liver 1 (2%)
Iliac, Sarcoma 1 (2%)
Mediastinal, Cholangiocarcinoma, Metastatic,
Liver 1 (2%)
Renal, Neoplasm NOS, Metastatic, Ovary 1 (2%)
Lymph Node, Mandibular (49) (47) (49)
Mast Cell Tumor Benign 1 (2%)
Lymph Node, Mesenteric (50) (49) (50)
Hemangiosarcoma 1 (2%)
Spleen (50) (50) (50)
Hemangiosarcoma 2 (4%) 3 (6%)
Thymus (48) (24) (47)
Fibrosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (49) (23) (50)
Adenocarcinoma 1 (2%) 1 (4%)
Skin (50) (26) (50)
Subcutaneous Tissue, Fibrosarcoma 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 2 (4%) 1 (4%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (1) (3)
Fibrosarcoma 1 (100%) 1 (33%)
Rhabdomyosarcoma 1 (33%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (26) (50)
Meningioma Benign 1 (2%)
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 05037-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PENTACHLOROANISOLE Date: 06/23/97
Route: GAVAGE Time: 12:31:18
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 20 MG/KG 40 MG/KG
CONTROL
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (27) (50)
Adenocarcinoma, Metastatic, Harderian Gland 2 (7%)
Alveolar/Bronchiolar Adenoma 2 (4%) 1 (4%) 1 (2%)
Alveolar/Bronchiolar Carcinoma 1 (4%) 1 (2%)
Cholangiocarcinoma, Metastatic, Liver 1 (2%)
Fibrosarcoma 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) 1 (2%)
Mediastinum, Fibrosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Ear (2) (1) (1)
Fibrosarcoma 1 (100%)
Harderian Gland (6) (2) (4)
Adenocarcinoma 2 (100%)
Adenoma 3 (50%) 4 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (25) (50)
Cholangiocarcinoma, Metastatic, Liver 1 (2%)
Urinary Bladder (49) (26) (47)
Hemangioma 1 (4%)
Histiocytic Sarcoma 1 (2%)
Sarcoma 1 (4%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50)
Histiocytic Sarcoma 1 (2%)
Lymphoma Malignant Histiocytic 1 (2%) 1 (2%)
Lymphoma Malignant Lymphocytic 2 (4%) 1 (2%) 8 (16%)
Lymphoma Malignant Mixed 4 (8%) 7 (14%) 4 (8%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 5
NTP Experiment-Test: 05037-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PENTACHLOROANISOLE Date: 06/23/97
Route: GAVAGE Time: 12:31:18
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 20 MG/KG 40 MG/KG
CONTROL
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 32 31 30
Total Primary Neoplasms 52 56 58
Total Animals with Benign Neoplasms 21 19 18
Total Benign Neoplasms 24 22 25
Total Animals with Malignant Neoplasms 19 20 23
Total Malignant Neoplasms 28 33 33
Total Animals with Metastatic Neoplasms 2 2 1
Total Metastatic Neoplasm 2 2 8
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 1
Total Uncertain Neoplasms 1
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 6
NTP Experiment-Test: 05037-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PENTACHLOROANISOLE Date: 06/23/97
Route: GAVAGE Time: 12:31:18
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 20 MG/KG 40 MG/KG
CONTROL
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50
Early Deaths
Natural Death 2 2
Moribund Sacrifice 17 20 22
Accidently Killed 1
Dosing Accident 1
Survivors
Terminal Sacrifice 30 27 27
Natural Death 1
Animals Examined Microscopically 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Small, Ileum (50) (22) (49)
Intestine Small, Jejunum (50) (23) (49)
Adenocarcinoma 1 (2%)
Liver (50) (50) (50)
Hemangiosarcoma 2 (4%) 5 (10%) 3 (6%)
Hemangiosarcoma, Multiple 3 (6%) 7 (14%)
Hepatocellular Carcinoma 7 (14%) 14 (28%) 9 (18%)
Hepatocellular Carcinoma, Multiple 2 (4%) 2 (4%) 3 (6%)
Hepatocellular Adenoma 18 (36%) 18 (36%) 13 (26%)
Hepatocellular Adenoma, Multiple 2 (4%) 6 (12%) 1 (2%)
Histiocytic Sarcoma 1 (2%)
Mesentery (2) (9) (4)
Fibrous Histiocytoma Malignant 1 (11%)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (25%)
Pancreas (50) (23) (50)
Fibrous Histiocytoma Malignant 1 (4%)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (2%)
Salivary Glands (50) (23) (50)
Stomach, Forestomach (50) (50) (50)
Fibrous Histiocytoma Malignant 1 (2%)
Squamous Cell Carcinoma 1 (2%)
Squamous Cell Papilloma 1 (2%)
Stomach, Glandular (50) (48) (49)
Squamous Cell Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
Page 7
NTP Experiment-Test: 05037-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PENTACHLOROANISOLE Date: 06/23/97
Route: GAVAGE Time: 12:31:18
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 20 MG/KG 40 MG/KG
CONTROL
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
None
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland (50) (50) (49)
Capsule, Spindle Cell, Adenoma 4 (8%) 2 (4%)
Adrenal Gland, Cortex (50) (50) (49)
Adenoma 1 (2%)
Capsule, Fibrous Histiocytoma Malignant 1 (2%)
Adrenal Gland, Medulla (50) (50) (48)
Pheochromocytoma Benign 4 (8%) 7 (15%)
Islets, Pancreatic (50) (23) (49)
Adenoma 1 (4%)
Fibrous Histiocytoma Malignant 1 (4%)
Thyroid Gland (50) (49) (50)
C-Cell, Carcinoma 1 (2%)
Follicular Cell, Adenoma 1 (2%)
Follicular Cell, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (1)
Mediastinum, Fibrosarcoma 1 (100%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (50) (24) (50)
Fibrous Histiocytoma Malignant 1 (4%)
Prostate (50) (23) (50)
Fibrous Histiocytoma Malignant 1 (4%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (4%)
Seminal Vesicle (50) (24) (50)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (2%)
Testes (50) (23) (50)
Interstitial Cell, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
Page 8
NTP Experiment-Test: 05037-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PENTACHLOROANISOLE Date: 06/23/97
Route: GAVAGE Time: 12:31:18
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 20 MG/KG 40 MG/KG
CONTROL
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (23) (50)
Hemangiosarcoma 1 (2%) 1 (2%)
Lymph Node (50) (50) (50)
Mediastinal, Fibrous Histiocytoma Malignant 1 (2%)
Mediastinal, Squamous Cell Carcinoma,
Metastatic, Stomach 1 (2%)
Lymph Node, Mandibular (48) (49) (49)
Lymph Node, Mesenteric (50) (49) (50)
Fibrous Histiocytoma Malignant 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (2%)
Spleen (50) (50) (50)
Hemangiosarcoma 3 (6%) 1 (2%) 5 (10%)
Thymus (49) (22) (50)
Thymoma Benign 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (29) (50)
Hemangioma 1 (2%)
Hemangiosarcoma 1 (3%)
Keratoacanthoma 1 (2%)
Subcutaneous Tissue, Hemangioma 2 (7%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (24) (50)
Osteosarcoma 2 (8%)
Skeletal Muscle (2)
Fibrosarcoma 1 (50%)
Hemangiosarcoma 1 (50%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (32) (50)
Alveolar/Bronchiolar Adenoma 6 (12%) 7 (22%) 4 (8%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%)
Alveolar/Bronchiolar Carcinoma 4 (8%) 4 (13%) 5 (10%)
Alveolar/Bronchiolar Carcinoma, Multiple 2 (4%) 1 (3%)
Page 9
NTP Experiment-Test: 05037-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PENTACHLOROANISOLE Date: 06/23/97
Route: GAVAGE Time: 12:31:18
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 20 MG/KG 40 MG/KG
CONTROL
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - cont
Hepatocellular Carcinoma, Multiple,
Metastatic, Liver 2 (6%) 2 (4%)
Hepatocellular Carcinoma, Metastatic, Liver 2 (4%) 1 (3%) 2 (4%)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Ear (1)
Fibrosarcoma 1 (100%)
Harderian Gland (2) (6) (4)
Adenoma 2 (100%) 6 (100%) 4 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (25) (50)
Hepatocellular Carcinoma, Metastatic, Liver 1 (4%)
Histiocytic Sarcoma 1 (2%)
Renal Tubule, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50)
Histiocytic Sarcoma 1 (2%)
Lymphoma Malignant Histiocytic 2 (4%) 1 (2%)
Lymphoma Malignant Lymphocytic 1 (2%)
Lymphoma Malignant Mixed 2 (4%) 4 (8%) 8 (16%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 10
NTP Experiment-Test: 05037-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PENTACHLOROANISOLE Date: 06/23/97
Route: GAVAGE Time: 12:31:18
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 20 MG/KG 40 MG/KG
CONTROL
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 38 47 46
Total Primary Neoplasms 64 94 82
Total Animals with Benign Neoplasms 29 36 25
Total Benign Neoplasms 37 46 32
Total Animals with Malignant Neoplasms 21 30 35
Total Malignant Neoplasms 27 48 50
Total Animals with Metastatic Neoplasms 2 4 5
Total Metastatic Neoplasm 2 5 9
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 11
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------